ImmunoGen Valuation
Is IMGN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IMGN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IMGN * (MX$268.5) is trading above our estimate of fair value (MX$191.61)
Significantly Below Fair Value: IMGN * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IMGN *?
Key metric: As IMGN * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is IMGN *'s PS Ratio? | |
|---|---|
| PS Ratio | 29.1x |
| Sales | US$287.61m |
| Market Cap | US$8.36b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 27.3x |
| Enterprise Value/EBITDA | -99.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does IMGN *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.3x | ||
1801 Innovent Biologics | 7.6x | 22.1% | HK$60.8b |
SOBI Swedish Orphan Biovitrum | 4x | 9.0% | SEK 102.5b |
300896 Imeik Technology DevelopmentLtd | 19.8x | 19.2% | CN¥60.9b |
002252 Shanghai RAAS Blood Products | 5.9x | 8.6% | CN¥49.1b |
IMGN * ImmunoGen | 29.1x | 26.0% | Mex$8.4b |
Price-To-Sales vs Peers: IMGN * is expensive based on its Price-To-Sales Ratio (29.1x) compared to the peer average (8.3x).
Price to Sales Ratio vs Industry
How does IMGN *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
| 277 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 277 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: IMGN * is expensive based on its Price-To-Sales Ratio (29.1x) compared to the Global Biotechs industry average (10.7x).
Price to Sales Ratio vs Fair Ratio
What is IMGN *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 29.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate IMGN *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Zai Lab
US$2.6b
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
ZLAB N
US$611.50
7D
0%
1Y
n/a